Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis is supported by a highly differentiated NeXT Personal MRD test with ultrasensitive 1ppm detection, multiple Medicare coverage wins across breast cancer, lung cancer, and pan-cancer IO monitoring, and growing clinician adoption that reached over 1,000 oncologists ordering the test as of Q1'26. It also has a meaningful commercialization catalyst through Tempus, which removes prior sales-force constraints and should accelerate access to a large MRD opportunity while complementing Personalis’s oncology data assets and bioPharma relationships. Despite gross margin volatility from 32% in 2024 to 23% in 2025 and 2% in Q1'26 before recovering to 21% in Q2'26, revenue guidance of $78-80M for 2026 and test volume growth of 7,815 in Q1'26 (+258% Y/Y) suggest improving operating momentum.

Personalis is facing a negative fundamental setup because its MRD and diagnostics businesses depend on payer coverage, partner execution, and pharma spending that can prove volatile or come in below expectations. The company also faces softness risk in biopharma demand, including for personalized cancer vaccines, while ordering and funding from large pharma and the VA can vary quarter-to-quarter in both size and frequency. Although the Tempus acquisition offers an exit at $16.25 per share and roughly $1.5B enterprise value, the deal remains exposed to a termination clause tied to Tempus stock and to uncertainty around closing terms in late 2026 or early 2027.